2/2 With over 20 featured scientists and more to come, we will continue working on this series to celebrate the path of knowledge in this fascinating field! .Check full interviews here:

1/2 The interview series "Reprogramming Stars" featured in Cellular Reprogramming, highlights the work of leaders in the field by introducing them and their science in exciting talks. @CellRepJrnl

2/2 Ervin showcased the exciting potential of dendritic cell reprogramming, expertly presenting his research – “Inducing humoral immunity across cancers with dendritic cell reprogramming uncovers biomarkers of response” and gathering enthusiasm from peers. Well done!.

1/2 Congrats to our PhD student @ervin_ascic for winning the best poster award in “Improving Immunity” at the 22nd #CIMT Annual Meeting, Europe's Cancer Immunotherapy Meeting, held this year in Mainz, Germany. His work was regarded as an interesting, state-of-the-art technology.

3/3 We are excited to be part of the team that will introduce DC reprogramming into clinical TIL therapy protocols, exploring the unlimited potential of this technology! @AsgardThx @Lunduniversity .For more, see:

2/3 Leveraging industrial, academic, and clinical expertise, Repro-TIL provides a solution to unlock the efficacy of tumor-infiltrating lymphocyte (TIL) therapy by using dendritic cell (DC) reprogramming to selectively expand antigen-specific tumor-reactive TILs.

1/3 We are excited to announce that the project Repro-TIL, standing for “Breakthrough Neoantigen-specific Tumor-Infiltrating Lymphocyte Therapies Through Novel Dendritic Cell Reprogramming”, was awarded a EIC Transition grant! @EUeic.

I am excited to share that I will presenting the latest advances in in vivo reprogramming for cancer immunotherapy at the Science Spotlight session during the #ISSCR2025 Annual Meeting in Hong Kong, June 11-14, 2025.

4/4 DCs are calling the shots once again! This work was led by Barbara Schraml’s lab (@buschraml, Munich, Germany) and had the collaboration of our amazing PhD student @AbigailRAltman. Full paper here: #DCs #autoimmunity #cancerimmunotherapy.

3/4 The twist is that while being distinct DC subtype, RORγt+ DCs have features of conventional DCs including migration to lymph nodes and ability to activate naïve CD4+ T cells. Hence this DC subtype shows potential for being targeted both in autoimmunity & cancer immunotherapy.

2/4 RORγt+ dendritic cells (DCs) are antigen-presenting cells with functions described in T cell tolerance. Narasimhan et al. found that RORγt+ DCs are conserved between mouse and human, presenting functional flexibility.

1/4 Celebrating our collaborative efforts, highlighted in the paper “RORγt-expressing dendritic cells are functionally versatile and evolutionarily conserved antigen presenting cells”, recently published in @PNASNews.

We recently had a great get-together joining the Pereira Lab and @AsgardThx, in an Interaction Day where all members shared their paths and aspirations. What a magnificent way to share a day with our teammates! ✨

3/3 This innovative strategy brings forward a first-in-class antigen-specific tumor-reactive T cell therapy, holding potential to transform treatment for hard-to-treat cancers. Well done, Camille! .For more info see:

2/3 Conventional therapies with tumor-infiltrating T cells (TILs) rely on unspecific expansion of T cells resected from tumor tissue. Camille’s project will use reprogramming of patients’ tumor cells into dendritic cells to selectively expand tumor-reactive T cells.

1/3 Congrats to our team member Camille Chatelain who was awarded a Marie Skłodowska-Curie Actions (MSCA) Postdoctoral Fellowship. Her project will advance a strategy for cancer therapy with tumor-reactive T cells! @MSCActions

2/2 Our pioneering strategy of inducing antitumor immunity with cell fate reprogramming can prove transformative for cancer immunotherapy. As a SciLifeLab Group Leader, I will continue to advocate for innovation, contributing to this amazing Swedish organization!.

1/2 I am proud to announce that I will join the SciLifeLab community as a Group Leader! @scilifelab is a health and environmental infrastructure that fosters a solid web of researchers collaborating within sectors such as industry and health care. Read 👇.

🌟Amazing full day of great discussions, 1-year progress updates & future planning as our @Eueic pathfinder #RESYNC consortium gathered in Turin. Exciting innovations ahead as we push the boundaries of chemical reprogramming!.#HorizonEurope .Read more:

3/3 For more details into the IGNITE Postdoc Fellow Program: